0
0
Proscia Raises $9M in Series C Extension
Proscia, a prominent provider of digital pathology software, has recently announced a significant development in its financial backing with the acquisition of $9 million in an extension of its Series C funding round. This additional capital injection elevates the total round to an impressive $46 million. The company’s financial boost follows closely on the heels of Proscia’s recent achievement of receiving FDA clearance for its innovative software platform, a milestone that greatly enhances its accessibility within the U.S. diagnostic market.
Investors
The Series C extension funding was spearheaded by Highline Capital Management and Triangle Peak Partners, along with participation from existing investors like Alpha Intelligence Capital, Scale Venture Partners, Hitachi Ventures, and others. These funds are earmarked to fuel Proscia’s commercial expansion initiatives and further the advancement of its AI-powered applications designed for life sciences and diagnostic laboratories.
“We’re ecstatic about this regulatory clearance as it paves the way for the sale of our diagnostic products in the U.S. market, especially during a time when global demand is critical,” stated David West, Proscia’s co-founder and CEO. “With this funding infusion, we are well-positioned to accelerate our mission of revolutionizing disease diagnostics and treatment, leveraging the potential of digital pathology data and AI technologies.”
Digital Pathology and AI Innovation
Proscia’s software platform is already in use by 14 of the top 20 pharmaceutical companies, harnessing extensive pathology image data to drive advancements in drug discovery and development. Securing the FDA clearance enables Proscia to introduce its digital pathology solutions to diagnostic labs, serving to address the escalating challenges posed by a global scarcity of pathologists and the rising incidence of cancer cases.
“Pathology data presents a significant infrastructure demand,” West explained. “It surpasses other medical data repositories by orders of magnitude, a rationale cited by companies like Nvidia regarding the role of AI in life sciences and the necessity for GPU technology. Our collaborations with cloud service giants such as AWS and Azure have simplified the process of achieving enterprise-scale capabilities.”
Proscia’s adoption of an open platform strategy empowers the company, its affiliates, and its clientele to design and implement AI applications targeting specific diseases and applications, resembling the model adopted by platforms like OpenAI’s ChatGPT app marketplace.
Leading Digital Pathology Transformation
With the surge in digital pathology adoption poised to reach full integration within the next 5-7 years, Proscia stands at the forefront of driving this transformative wave. The AI applications developed by the company automate critical tasks such as quality control and tumor identification, streamlining pathologists’ workflow and enabling them to concentrate on higher-order analysis.
“For quite some time, Silicon Valley had somewhat disregarded pathology as a niche area due to its rigorous regulations and data complexity,” West noted. “However, it represents a substantial market with significant impact potential. We are committed to delivering exceptional software solutions tailored to the field of pathology.”
Backed by its recent funding boost and FDA approval, Proscia is poised to realize this vision, ushering in an era of data-driven, AI-enhanced pathology that could significantly enhance patient outcomes. As the integration of digital pathology and AI technologies gains momentum, Proscia’s approach of open platform deployment and enterprise-oriented solutions positions it as a pivotal player in the rapidly evolving healthcare technology landscape.
Image/Photo credit: source url
